Mary S. Campbell

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde et al. · New England Journal of Medicine · 2021 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett et al. · Blood · 2017 · 320 citations · Full text

Medicine, Hematology, Oncology +15

Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission

Jared M. Baeten, Erin Kahle, Jairam R. Lingappa et al. · Science Translational Medicine · 2011 · 296 citations

Life Sciences, Infectious Diseases, Molecular Biology +14

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell et al. · The Lancet Oncology · 2021 · 267 citations

Medicine, Oncology, Pharmacology +14

Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk

Jairam R. Lingappa, James P. Hughes, Richard S. Wang et al. · PLoS ONE · 2010 · 180 citations · Full text

Public Health, Biostatistics, Infectious Diseases +14